Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma Associated with Nephrotic Syndrome during Hemodialysis, Treated Successfully with Tirabrutinib.

Yasunobu Sekiguchi, You Nishimura, Hiroaki Kanda, Machiko Kawamura, Kazuhiko Kobayashi, Hirofumi Kobayashi

Open access · diamondAbstract readCase Reports

In one paragraph

Article in Internal medicine (Tokyo, Japan), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.2field-weighted citation impact, top 54% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yasunobu SekiguchiDepartment of Hematology, Saitama Cancer Center, Japan.

You NishimuraDepartment of Pathology, Saitama Cancer Center, Japan.

Hiroaki KandaDepartment of Pathology, Saitama Cancer Center, Japan.

Machiko KawamuraDepartment of Clinical Laboratory Medicine, Saitama Cancer Center, Japan.

Kazuhiko KobayashiDepartment of Clinical Laboratory Medicine, Saitama Cancer Center, Japan.

Hirofumi KobayashiDepartment of Hematology, Saitama Cancer Center, Japan.

Saitama Cancer Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 74-year-old woman was diagnosed with Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) in X-18. Fludarabine plus rituximab (FR) was started, and she showed remission. In July X-7, the serum creatinine (Cr) level increased to 1.67 mg/dL, and bendamustine plus rituximab (BR) was started. By November X-7, the Cr level had increased to 8.41 mg/dL, so she was started on hemodialysis (HD). In September X-1, she developed nephrotic syndrome. She was started on tirabrutinib at 480 mg. In July X, her nephrotic syndrome had improved, and a complete response (CR) was achieved. This is the first case of the administration of tirabrutinib in a patient undergoing HD.

Indexed as

LymphomaNephrotic SyndromeWaldenstrom MacroglobulinemiaAgedFemaleHumansImidazolesPyrimidinesRenal DialysisRituximabImidazolesPyrimidinesRituximabtirabrutinibchronic renal failurehemodialysisnephrotic syndrometirabrutinibWaldenstrom macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL)

Identifiers

PMID35110483

DOI10.2169/internalmedicine.8760-21

PMCPMC9449620

OpenAlexW4210815376

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.